Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg

FDA approves Alembic’s Paroxetine ER tablets

Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder

Enveric clears FDA feedback milestone, prepares IND submission for EB-003

IND application for EB-003 expected in early 2026

Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule

Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders

CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings

Morrisons introduces sensory support boxes in store for autistic and neurodiverse customers

Sensory Boxes include items such as drawing boards and fidget balls to support management of anxiety and improve shopping experience

Dr. Prabhavathi. R joins HEJJE

Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders

Schizophrenia in Children: Understanding Early-Onset Schizophrenia

Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia

Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress

The company will also share results in two additional posters for deuruxolitinib

Aayush Wellness enters nutraceutical market with Dreamy Sleep Gummies